Letters Cytisine to stop smoking

The case for licensing cytosine now for smoking cessation is overwhelming

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f5736 (Published 25 September 2013) Cite this as: BMJ 2013;347:f5736
  1. John A Stapleton, reader in addictions statistical analyses1
  1. 1King’s College London, Institute of Psychiatry, London SE5 8AF, UK
  1. john.stapleton{at}kcl.ac.uk

Prochaska and colleagues’ excellent overview of cytisine in smoking cessation fails to highlight the compelling cost-benefit evidence on why this effective, safe, and inexpensive drug should be licensed immediately worldwide.1 This case has already been made,2 and readers interested in this drug and the inflexibility of Western regulatory systems are directed to this article. …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe